公开(公告)号：US20130085079A1

公开(公告)日：2013-04-04

申请号：US13631567

申请日：2012-09-28

Applicant: SOMALOGIC, INC.

Inventor： Rosalynn Dianne GILL ,  Stephen Alaric WILLIAMS ,  Alex A.E. STEWART ,  Robert MEHLER ,  Trudi FOREMAN ,  Britta SINGER

IPC: C40B30/04 ,  C40B40/06 ,  C40B40/10

CPC classification number: G01N33/6872 ,  G01N33/6893 ,  G01N2333/51 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

公开(公告)号：US20150168423A1

公开(公告)日：2015-06-18

申请号：US14145026

申请日：2013-12-31

Applicant: SOMALOGIC, INC.

Inventor： Rosalynn Dianne GILL ,  Stephen Alaric WILLIAMS ,  Alex A.E. STEWART ,  Robert MEHLER ,  Trudi FOREMAN ,  Britta SINGER

IPC: G01N33/68

CPC classification number: G01N33/6872 ,  G01N33/6893 ,  G01N2333/51 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

Abstract translation: 本公开内容包括用于在5年内评估心血管（CV）事件的风险的生物标志物，方法，装置，试剂，系统和试剂盒。 一方面，本公开提供可以单独使用或以各种组合使用以评估5年内CV事件的风险的生物标志物。 在另一方面，提供了用于在个体中评估5年内的CV事件的风险的方法，其中所述方法包括在来自个体的生物样品中检测至少一个对应于选自组中的生物标志物的生物标记值 在另一方面，提供了用于评估CV的风险的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于至少一种选自以下的生物标志物的生物标记值 该组生物标志物在表2中提供。在另一方面，提供了用于评估个体中CV事件的风险的方法，通常在5年内，其中所述方法包括在来自个体的生物样品中至少检测 一个生物标记值对应于选自表3中提供的生物标志物组的至少一种生物标志物。